Literature DB >> 1480770

Clinical implications of heterogeneity of tumor response to radiation therapy.

H Suit1, S Skates, A Taghian, P Okunieff, J T Efird.   

Abstract

Heterogeneity of response of tumor tissue to radiation clearly exists. Major parameters include histopathologic type, size (number of tumor rescue units (TRUs)), hemoglobin concentration, cell proliferation kinetics and immune rejection reaction by host. Further, normal and presumably tumor tissue response is altered in certain genetic diseases, e.g. ataxia telangiectasia. Any assessment of response of tumor tissue to a new treatment method or the testing of a new clinical response predictor is optimally based upon a narrow strata, viz., uniform with respect to known parameters of response, e.g. size, histological type. Even among tumors of such a clinically defined narrow strata, there will be residual heterogeneity with respect to inherent cellular radiation sensitivity, distributions of pO2, (SH), cell proliferation etc. The value of a response predictor of an individual tumor will be determined by the heterogeneity of values for these and or other characteristics and by the coefficient of variation (CV) of the measured values of the individual parameters. Heterogeneity of one or more parameters of response is reflected in the slope of the dose response curve for local control, viz. the greater the heterogeneity the less steep the slope. To examine for this effect, the slope of dose response curves for control of model tumors of 10(8) tumor rescue units (TRU) and the SF2 = 0.5 (survival fraction after a single dose of 2 Gy) has been used to assess the impact of inter- and intra-tumoral variation of SF2 on slope, defined as gamma 50 values. The gamma 50 is the increase in local control expressed in percent points for a one percentage increment in dose, at the mid-point on the dose-response curve. The gamma 50 was 6.5 for CV = 0.0. For inter-tumoral CVs of 10%, 20% and 40%, the gamma 50 rapidly decreased to 2.4, 1.3 and 0.7. Intra-tumoral variation was less important, viz., for CVs of 10%, 20%, and 40% the gamma 50 values were reduced to 5.3, 3.8 and 2.2. Combining inter- and intra-tumoral variation reduced the gamma 50 only slightly below that for inter-tumoral variation alone. For example, were the CV 10% for inter- and intra-tumoral variation, the gamma 50 would be 2.1 as compared to 2.4 for inter-tumoral variation alone. The number of TRUs also affects slope, viz. gamma 50 increased from 1 to 9.7 as the TRU number increased from 10(1) to 10(12).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1480770     DOI: 10.1016/0167-8140(92)90244-o

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  18 in total

Review 1.  Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling.

Authors:  Nitin Ohri; Adam P Dicker; Edouard J Trabulsi; Timothy N Showalter
Journal:  Eur J Cancer       Date:  2011-09-22       Impact factor: 9.162

2.  Risk-adaptive optimization: selective boosting of high-risk tumor subvolumes.

Authors:  Yusung Kim; Wolfgang A Tomé
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-01       Impact factor: 7.038

3.  On the radiobiological impact of metal artifacts in head-and-neck IMRT in terms of tumor control probability (TCP) and normal tissue complication probability (NTCP).

Authors:  Yusung Kim; Wolfgang A Tomé
Journal:  Med Biol Eng Comput       Date:  2007-06-16       Impact factor: 2.602

4.  Predicting in vivo glioma growth with the reaction diffusion equation constrained by quantitative magnetic resonance imaging data.

Authors:  David A Hormuth; Jared A Weis; Stephanie L Barnes; Michael I Miga; Erin C Rericha; Vito Quaranta; Thomas E Yankeelov
Journal:  Phys Biol       Date:  2015-06-04       Impact factor: 2.583

Review 5.  Predicting outcomes in radiation oncology--multifactorial decision support systems.

Authors:  Philippe Lambin; Ruud G P M van Stiphout; Maud H W Starmans; Emmanuel Rios-Velazquez; Georgi Nalbantov; Hugo J W L Aerts; Erik Roelofs; Wouter van Elmpt; Paul C Boutros; Pierluigi Granone; Vincenzo Valentini; Adrian C Begg; Dirk De Ruysscher; Andre Dekker
Journal:  Nat Rev Clin Oncol       Date:  2012-11-20       Impact factor: 66.675

Review 6.  Radiation oncology in the era of precision medicine.

Authors:  Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld
Journal:  Nat Rev Cancer       Date:  2016-03-18       Impact factor: 60.716

7.  Oxygen distributions partly explain the radiation response of human squamous cell carcinomas.

Authors:  P Okunieff; J de Bie; E P Dunphy; D J Terris; M Höckel
Journal:  Br J Cancer Suppl       Date:  1996-07

8.  Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer.

Authors:  William T C Yuh; Nina A Mayr; David Jarjoura; Dee Wu; John C Grecula; Simon S Lo; Susan M Edwards; Vincent A Magnotta; Steffen Sammet; Hualin Zhang; Joseph F Montebello; Jeffrey Fowler; Michael V Knopp; Jian Z Wang
Journal:  Invest Radiol       Date:  2009-06       Impact factor: 6.016

9.  Usefulness of chemoradiotherapy for inoperable gastric cancer.

Authors:  T Taki; Y Hoya; A Watanabe; T Nakayoshi; T Okamoto; H Sekine; N Mitsumori; K Yanaga
Journal:  Ann R Coll Surg Engl       Date:  2016-09-23       Impact factor: 1.891

10.  Comparison of the response of human FaDu squamous cell carcinoma in nude mice after hypofractionated-accelerated regimens and "curative" fractionation schedules.

Authors:  S Appold; M Baumann; C Petersen; K Horn; F Eichhorn
Journal:  Strahlenther Onkol       Date:  1998-06       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.